Myriad Genetic (NASDAQ:MYGN) and Illumina (NASDAQ:ILMN) announce the expansion of a strategic partnership to broaden access to and availability of oncology homologous recombination deficiency (HRD) ...

Myriad Genetics, Inc. MYGN recently announced a collaboration with GSK plc GSK to advance in the field of genetic testing. The latest development is intended to improve access to homologous ...

BARCELONA, Spain & MONTPELLIER, France--(BUSINESS WIRE)--SeqOne, provider of new generation genomic analysis solutions for personalized medicine, is announcing at the ESMO GYNAE conference a new HRD ...

You might hear some unfamiliar terms when you talk to your doctor about testing. There are multiple types of tests, and they provide different sorts of information.

Myriad Genetics, Inc. MYGN recently announced the expansion of a strategic partnership with Illumina Inc. ILMN to widen access to oncology homologous recombination deficiency (HRD) testing in the ...

The TSO 500 HRD research test aligns Myriad's gold standard MyChoice® CDx HRD technology with Illumina's pan-cancer test, TSO 500. The test was codeveloped with Merck (known as MSD outside the US and ...

Tesaro has made a deal with Myriad Genetics to use Myriad's homologous recombination deficiency (HRD) test to look for tumor types that may respond to its poly-ADP ribose polymerase (PARP) inhibitor, ...

B-Cell–Mediated Immunity Predicts Survival of Patients With Estrogen Receptor–Positive Breast Cancer To meet the urgent need for accessible homologous recombination-deficient (HRD) test options, we ...

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in ...

Dr. Normanno will present the experience of his laboratory evaluating the Ion Torrent Oncomine Comprehensive Assay Plus*, a targeted NGS approach that can help clinical research in identifying all ...